KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Debt: 2017-2024

Historic Total Debt for Alnylam Pharmaceuticals (ALNY) over the last 5 years, with Dec 2024 value amounting to $93.8 million.

  • Alnylam Pharmaceuticals' Total Debt was N/A to $121.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year change of. This contributed to the annual value of $93.8 million for FY2024, which is N/A change from last year.
  • Alnylam Pharmaceuticals' Total Debt amounted to $93.8 million in FY2024, which was down 86.12% from $675.7 million recorded in FY2021.
  • Alnylam Pharmaceuticals' 5-year Total Debt high stood at $675.7 million for FY2021, and its period low was $93.8 million during FY2024.
  • In the last 1 years, Alnylam Pharmaceuticals' Total Debt had a median value of $93.8 million in 2024 and averaged $93.8 million.
  • Data for Alnylam Pharmaceuticals' Total Debt shows a peak YoY spiked of 253.25% (in 2021) over the last 5 years.
  • Over the past 3 years, Alnylam Pharmaceuticals' Total Debt (Yearly) stood at $191.3 million in 2020, then spiked by 253.25% to $675.7 million in 2021, then reached $93.8 million in 2024.